LoDoCo2 - Low-dose colchicine in coronary disease

Reported from the European Society of Cardiology ESC Congress 2020

Reported from ESC Congress 2020 - Massimo Imazio (Turin, Italy) discusses with Dejan Milasinovic the results of the LoDoCo2 trial which showed that Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease.

Prof. Imazio answers the following questions:

What is the role of Colchicine in coronary artery disease?
Could you talk about the LoDoCo1 trial which preceded LoDoCo2?
Could you describe the design and the main results of LoDoCo2?
What are the clinical implications in terms of side effects?
Do you think the results may be applied to patients with chronic coronary syndromes who have had previous history of ACS?